- Home
- NCLH vs RVNC Comparison
NCLH vs RVNC Comparison
Compare NCLH & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCLH
- RVNC
- Stock Information
- Founded
- NCLH 1966
- RVNC 1999
- Country
- NCLH United States
- RVNC United States
- Employees
- NCLH N/A
- RVNC N/A
- Industry
- NCLH Marine Transportation
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- NCLH Consumer Discretionary
- RVNC Health Care
- Exchange
- NCLH Nasdaq
- RVNC Nasdaq
- Market Cap
- NCLH 12.1B
- RVNC 320.5M
- IPO Year
- NCLH 2013
- RVNC 2014
- Fundamental
- Price
- NCLH $26.92
- RVNC $3.09
- Analyst Decision
- NCLH Buy
- RVNC Hold
- Analyst Count
- NCLH 16
- RVNC 9
- Target Price
- NCLH $29.27
- RVNC $8.45
- AVG Volume (30 Days)
- NCLH 9.1M
- RVNC 3.6M
- Earning Date
- NCLH 10-31-2024
- RVNC 11-07-2024
- Dividend Yield
- NCLH N/A
- RVNC N/A
- EPS Growth
- NCLH N/A
- RVNC N/A
- EPS
- NCLH 1.25
- RVNC N/A
- Revenue
- NCLH $9,356,741,000.00
- RVNC $256,945,000.00
- Revenue This Year
- NCLH $13.10
- RVNC $11.28
- Revenue Next Year
- NCLH $8.05
- RVNC $27.21
- P/E Ratio
- NCLH $21.52
- RVNC N/A
- Revenue Growth
- NCLH 15.76
- RVNC 25.82
- 52 Week Low
- NCLH $14.69
- RVNC $2.30
- 52 Week High
- NCLH $28.64
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- NCLH 53.50
- RVNC 33.47
- Support Level
- NCLH $24.89
- RVNC $3.06
- Resistance Level
- NCLH $26.90
- RVNC $3.09
- Average True Range (ATR)
- NCLH 1.04
- RVNC 0.11
- MACD
- NCLH -0.23
- RVNC 0.02
- Stochastic Oscillator
- NCLH 56.86
- RVNC 6.90
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.